CE 125
Alternative Names: CE-125; CE125-PNP-IBRLatest Information Update: 03 Mar 2022
At a glance
- Originator Cello Therapeutics
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lymphoma
Most Recent Events
- 17 Feb 2022 Cello Therapeutics has patent protection for membrane encapsulate nanoparticles in Taiwan, China, Macao, Japan, Europe (Cello Therapeutics pipeline, February 2022)
- 17 Feb 2022 Cello Therapeutics has patents pending for membrane encapsulate nanoparticles in Hong Kong, China, USA, Europe, Canada and worldwide (Cello Therapeutics pipeline, February 2022)
- 17 Feb 2022 Preclinical trials in Lymphoma in USA (unspecified route) (Cello Therapeutics pipeline, February 2022)